Featured News
(OBR) Jan 16, 2021 - A Phase 2 trial demonstrated the safety of adding pembrolizumab to neoadjuvant chemoradiation to treat locally advanced rectal cancer (LARC). However, it failed to meet a primary endpoint of improving the neoadjuvant...
2021 GI Cancers Symposium: Preop Therapy Does Not Raise Surgical Risks in Thoracic Esophageal Cancer
(OBR) Jan 16, 2021 - Adding docetaxel or radiotherapy to cisplatin plus 5-fluorouracil as preoperative therapy does not appear to increase the risk of perioperative complications or mortality in patients with locally advanced, potentially...
(ASCO Daily News) Jan 16, 2021 - Serial analysis of circulating tumor DNA (ctDNA) after surgery can identify patients with stage I-III colorectal cancer (CRC) at high risk for recurrence.
(ASCO Daily News) Jan 16, 2021 - Patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant therapy with modified FOLFIRINOX (mFOLFIRINOX) had an 18-month overall survival (OS) rate of 66.4% in a...
(ASCO Daily News) Jan 15, 2021 - Updated data on the JACCRO GC-07 trial presented during the 2021 Gastrointestinal Cancers Symposium based on a median follow-up of 42.5 months not only confirmed the RFS results previously seen but...
More News
(ASCO Daily News) Jan 16, 2021 - Patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant therapy with modified FOLFIRINOX (mFOLFIRINOX) had an 18-month overall survival (OS) rate of 66.4% in a...
(ASCO Daily News) Jan 15, 2021 - Updated data on the JACCRO GC-07 trial presented during the 2021 Gastrointestinal Cancers Symposium based on a median follow-up of 42.5 months not only confirmed the RFS results previously seen but...
(ASCO Daily News) Jan 15, 2021 - Findings from the observational DELIVER trial sponsored by the Japan Clinical Cancer Research Organization showed that patients with advanced gastric cancer who responded to nivolumab treatment had a more...
(Yahoo! Finance) Jan 15, 2021 - Five Prime Therapeutics today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced...
(OBR) Jan 15, 2021 - Adding bemarituzumab to modified FOLFOX (mFOLFOX) chemotherapy significantly improves survival and response rates for patients with advanced gastric cancer. The approach was associated with an increase in corneal...
(Morningstar) Jan 15, 2021 - Puma Biotechnology, Inc. announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastrointestinal Cancers Symposium hosted by the American...
(Fight Colorectal Cancer) Jan 14, 2021 - Fight CRC’s research, titled Understanding the impact of COVID-19 on the colorectal cancer community: Barriers and Opportunities for Care, will be presented at the 2021 Gastrointestinal Cancer...
(Yahoo! Finance) Jan 15, 2021 - Zymeworks Inc. today announced new and updated clinical data for the HER2‑targeted bispecific antibody zanidatamab, in both HER2-expressing biliary tract cancer (BTC) and gastroesophageal adenocarcinoma...
(Morningstar) Jan 15, 2021 - AVEO Oncology today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor...
(Morningstar) Jan 15, 2021 - NantKwest and ImmunityBio’s QUILT 88 trial shows novel combination immunotherapy, which includes aldoxorubicin, has more than doubled historic median survival rates in patients.
Follow @OBRTweets